Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Relapse after HSCT 2021 | Management of relapse after CAR-T in patients with B-cell lymphoma

Peter Dreger, MD, Heidelberg University Hospital, Heidelberg, Germany, describes the management of patients with B-cell lymphomas relapsing following treatment with CD19-targeted chimeric antigen receptor (CAR) T-cells, commenting on the role of allogeneic hematopoietic stem cell transplantation. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.